Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2CNS 1

Conditions

Breast Neoplasms 672Carcinoma, Non-Small-Cell Lung 461Prostatic Neoplasms 390Neoplasms 382Lung Neoplasms 266Multiple Myeloma 246Colorectal Neoplasms 235Neoplasm Metastasis 217Melanoma 203Ovarian Neoplasms 166Leukemia, Myeloid, Acute 166Pancreatic Neoplasms 155Squamous Cell Carcinoma of Head and Neck 141Carcinoma, Renal Cell 141Lymphoma 137Brain Neoplasms 132Leukemia, Lymphocytic, Chronic, B-Cell 126Glioblastoma 126Recurrence 124Lymphoma, Non-Hodgkin 123Carcinoma, Hepatocellular 119Head and Neck Neoplasms 115Urinary Bladder Neoplasms 111Triple Negative Breast Neoplasms 110Stomach Neoplasms 110Precursor Cell Lymphoblastic Leukemia-Lymphoma 105Uterine Cervical Neoplasms 102Hematologic Neoplasms 100Lymphoma, Follicular 96Sarcoma 95

Interventions

tucatinib 1pertuzumab 1atezolizumab 1Trastuzumab 1Fulvestrant 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × HER2-positive Metastatic Breast Cancer × 1 year × Clear all
NCT03417544 2026-04-27

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
19 enrolled 26 charts
BreastCNS

HER2-positive Metastatic Breast Cancer

NCT05230810 2026-03-16

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

Criterium, Inc.

Phase 1/2 Active not recruiting
40 enrolled
Breast

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡